Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | CDC42BPB | Q9Y5S2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL459256 | 0.89 | ALDH1A1 (0.48) | GAALMNAALDH1A1KDM4EMAPT | |
| SCHEMBL426180 | 0.87 | MAPK1 (0.46) | GAALMNAXDHROCK2ROCK1 | |
| SCHEMBL28509985 | 0.86 | GAA (0.45) | GAALMNAALDH1A1MAPTHSD17B10 | |
| SCHEMBL430134 | 0.86 | ESR2 (0.36) | GAALMNAALDH1A1KDM4EMAPT | |
| SCHEMBL427905 | 0.86 | LMNA (0.45) | GAALMNAALDH1A1KDM4EMAPT | |
| SCHEMBL426688 | 0.84 | LMNA (0.58) | GAALMNAROCK1ALDH1A1KDM4E | |
| SCHEMBL427904 | 0.84 | LMNA (0.37) | GAALMNAROCK1ALDH1A1MAPT | |
| SCHEMBL3753301 | 0.84 | ALDH1A1 (0.39) | GAALMNAALDH1A1KDM4EMAPT | |
| SCHEMBL29554269 | 0.82 | MAPT (0.40) | GAAROCK1ALDH1A1KDM4EMAPT | |
| SCHEMBL31485111 | 0.82 | KDM4E (0.50) | GAAROCK1ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705291-A1 | IKK-ALPHA INHIBITORS | Cancer Research Technology Limited (GB) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024228035-A1 | IKK-ALPHA INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-11-07 | — | — | WO | disclosed |
| CN-112243439-A | Pyrrolo [2,3-B ] pyridines or pyrrolo [2,3-B ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2021-01-19 | — | — | CN | disclosed |
| US-9745311-B2 | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors | INCYTE CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745311-B2 | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors | INCYTE CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745311-B2 | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors | INCYTE CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160280713-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | INCYTE CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-20160280713-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | INCYTE CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-20160280713-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | INCYTE CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-9388185-B2 | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-07-12 | — | — | US | disclosed |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| EP-2178874-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | GAA 706/4885LMNA 3998/4885XDH 781/4885 |
| US-20160280713-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | FGFR1, FGFR2, FGFR3 | GAA 1066/4885LMNA 4755/4885XDH 1914/4885 |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | GAA 706/4885LMNA 3998/4885XDH 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.